Chronic hepatitis (HCV) among intravenous drug users (IDU); reasons for not initiating the antiviral treatment;Hepatitis crónica por VHC en la población usuaria de drogas por vía parenteral. Motivos para no iniciar el tratamiento antiviral

Adicciones

Volumn 13, Issue 4, 2001, Pages 399-405

  Crespo, Javier ^a   Garcia, F ^a   Castro, B ^a   Pons, F ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Chronic hepatitis; HCV; IDU; IFN; Ribavirin; Treatment

Indexed keywords

ANTIVIRUS AGENT; ILLICIT DRUG; INTERFERON; RIBAVIRIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC LIVER DISEASE; COMORBIDITY; DEMOGRAPHY; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; HUMAN TISSUE; ILLNESS BEHAVIOR; INTRAVENOUS DRUG ABUSE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PREVALENCE; TREATMENT CONTRAINDICATION;

EID: 0035698565     PISSN: 02144840     EISSN: None     Source Type: Journal    
DOI: 10.20882/adicciones.554     Document Type: Article

References (30)

1. Hepatitis C virus antibodies among risk groups in Spain
2. Clinical outcomes after transfusion-associated hepatitis C
3. The natural history of community-acquired hepatitis C in the United States
4. Hepatitis C and alcohol
5. Hepatitis C viremia in chronic active hepatitis B. Prevalence and clinical significance
6. Infección por los virus de la hepatitis B y C en los pacientes con carcinoma hepatocelular
7. Progresión de la fibrosis hepática en la hepatitis crónica C
8. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C
9. Interferon alpha 2-b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
10. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
11. Interferon alfa-2b plus ribavirin for chronic hepatitis C patients who have not responded to interferon monotherapy
12. Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum
13. Tratamiento de la hepatitis crónica
14. Tratamiento de la hepatitis crónica C
15. A survey of adverse events in 11.241 patients with chronic viral hepatitis treated with alfa interferon
16. Therapy of hepatitis C
17. Cost effectiveness of the treatment of chronic hepatitis C with interferon-alpha
18. EASL International Consensus Conference on Hepatitis C
19. Inter and intra-observer variation in the assessment of liver biopsy of chronic hepatitis C
20. A comparison of three interferon alpha-2b regimens for long-term treatment of chronic non-A, non-B hepatitis
21. Impact of alcohol on the histological and clinical progression of hepatitis C infection
22. Effects of alcohol consumption on histological changes in chronic hepatitis C: A clinicopathological study
23. Clinical toxicity of the interferons
24. Side effects of alpha interferon
25. Side effects of alpha-interferon therapy
26. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review
27. ¿Por qué no se tratan todos los pacientes con una hepatitis crónica C?
28. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity
29. Virological characterization and liver histology in HCV positive subjects with normal and elevated ALT levels
30. Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: A pilot randomized controlled study